— Know what they know.
Not Investment Advice

NUVL Earnings

Nuvalent, Inc.
1W: +0.0% 1M: +0.4% 3M: +14.5% YTD: +22.9% 1Y: +48.6% 3Y: +199.1%
$123.96
Last traded 2026-07-21 — delisted
NASDAQ · Healthcare · Biotechnology · $9.1B mcap · 49M float · 4.74% daily turnover · Short 40% of daily vol
Last Earnings 2026-05-07
EPS
$-1.39
▼ Miss -3.0%
Revenue
$486K
Est (actual pending)
Next Earnings 2026-08-06
EPS Estimate
$-1.35
Range: $-1.35 - $-1.35
Revenue Estimate
$13M
2 analysts

Estimate vs Actual

Earnings Surprise History

6/19
EPS Beats
0/19
Revenue Beats
32%
EPS Beat Rate
0%
Rev Beat Rate

Wall Street Forward Estimates

Quarterly
Annual

Estimate Revisions

Recent Revisions
DatePeriodFiscal DateEPS OldEPS NewChangeRev OldRev New
2026-06-29 annual 2029-12-31 $2.82 $2.82 — $940,697,182 $940,663,318
2026-06-29 quarter 2027-09-30 $-1.11 $-1.11 — $45,452,500 $45,447,833
2026-06-29 quarter 2026-09-30 $-1.46 $-1.44 ▲ 0.02 $2,193,500 $2,178,357
2026-06-29 quarter 2026-06-30 $-1.42 $-1.41 ▲ 0.01 $245,455 $245,455
2026-06-29 quarter 2027-12-31 $-0.80 $-0.82 ▼ 0.02 $62,907,333 $62,909,000
2026-06-29 quarter 2026-12-31 $-1.42 $-1.42 — $10,761,411 $9,876,274
2026-06-29 annual 2026-12-31 $-5.66 $-5.65 ▲ 0.01 $12,010,555 $11,221,252
2026-06-29 quarter 2027-03-31 $-0.97 $-0.97 — $49,942,143 $49,948,143
2026-06-29 quarter 2027-06-30 $-1.26 $-1.26 — $31,710,667 $31,708,167
2026-06-29 annual 2027-12-31 $-4.37 $-4.35 ▲ 0.02 $188,277,307 $187,798,613
2026-06-10 quarter 2026-09-30 $-1.44 $-1.46 ▼ 0.02 $2,047,267 $2,193,500
2026-06-10 quarter 2026-12-31 $-1.40 $-1.42 ▼ 0.02 $10,474,666 $10,761,411
2026-06-10 quarter 2026-06-30 $-1.41 $-1.42 ▼ 0.01 $245,455 $245,455
2026-06-10 annual 2027-12-31 $-4.47 $-4.37 ▲ 0.10 $181,020,607 $188,277,307
2026-06-10 annual 2029-12-31 $2.67 $2.82 ▲ 0.15 $908,055,750 $940,697,182
Earnings Call Transcripts
No transcripts available.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms